Substance / Medication

Rivastigmine

Overview

Active Ingredient
rivastigmine
RxNorm CUI
183379
Labeler: Zydus Lifesciences LimitedUpdated: 2025-11-17T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
The effects of rivastigmine on neuropsychiatric symptoms in the early stages of Parkinson's disease: A systematic review.
Reilly Siobhan, Dhaliwal Simran, Arshad Usman et al. · Eur J Neurol · 2024
PMID: 37975761Meta-AnalysisFull text (PMC)
Rivastigmine for treatment-refractory posttraumatic stress disorder: a systematic review.
Maguire P A, Bastiampillai T, Allison S et al. · East Asian Arch Psychiatry · 2024
PMID: 38955788Meta-Analysis
Effects of rivastigmine on gait in patients with neurodegenerative disorders: A systematic review and meta-analysis.
Shim Sung Ryul, Kim Jong-Yeup, Kwon Kyum-Yil et al. · PLoS One · 2024
PMID: 39666629Meta-AnalysisFull text (PMC)
Rivastigmine for Alzheimer's disease.
Birks Jacqueline S, Grimley Evans John · Cochrane Database Syst Rev · 2015
PMID: 25858345Meta-Analysis
Long-term effectiveness of rivastigmine patch or capsule for mild-to-severe Alzheimer's disease: a meta-analysis.
Su Jiangli, Liu Yang, Liu Yu et al. · Expert Rev Neurother · 2015
PMID: 26289489Meta-Analysis
Rivastigmine for vascular cognitive impairment.
Birks Jacqueline, McGuinness Bernadette, Craig David · Cochrane Database Syst Rev · 2013
PMID: 23728651Meta-AnalysisFull text (PMC)
A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Di Santo Simona Gabriella, Prinelli Federica, Adorni Fulvio et al. · J Alzheimers Dis · 2013
PMID: 23411693Meta-Analysis
Rivastigmine for dementia in people with Down syndrome.
Mohan Monica, Bennett Cathy, Carpenter Peter K · Cochrane Database Syst Rev · 2009
PMID: 19160344Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Rivastigmine (substance)
SNOMED CT
395868008
UMLS CUI
C0649350
RxNorm CUI
183379
Labeler
Zydus Lifesciences Limited

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.